A Phase 3 interventional study of Vortioxetine (Lu AA21004) and Venlafaxine extended release in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-10-13.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 26th largest by enrollment, is one of 3 that started in 2012, is one of 31 in phase 3, and was the 24th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 437 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 15th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2012, is one of 21 in phase 3, and was the 16th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other inclusion criteria may apply.
Exclusion Criteria:
Drug: Vortioxetine (Lu AA21004)
Drug: Venlafaxine extended release
10 mg/day
Also known as: Brintellix
150 mg/day
Also known as: Efexor® XL
Change From Baseline in MADRS Total Score at Week 8
Montgomery and Asberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at two-point intervals. The total score of the ten items ranges from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Baseline and Week 8
Change in CGI-S Score From Baseline to Week 8
Clinical Global Impression Scale - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients). Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Baseline and Week 8
CGI-I Score at Week 8
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not. Higher score = more affected.
Time frame: Week 8
Change in HAM-A Total Score From Baseline to Week 8
Hamilton Anxiety Rating Scale (HAM-A) is a 14-item rating scale designed to assess the global anxiety. Each symptom is rated from 0 (absent) to 4 (maximum severity). The total score of the 14 items ranges from 0 to 56. Higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Baseline and Week 8
MADRS Response at Week 8 (Response Defined as a ≥50% Decrease in the MADRS Total Score From Baseline)
Time frame: Week 8
Remission at Week 8 (Remission Defined as a MADRS Total Score ≤10)
Time frame: Week 8
Number of Adverse Events
Time frame: Baseline to Week 12
In- or outpatients with a primary diagnosis of recurrent of Major Depressive Disorder (MDD) were recruited for this study from China, South Korea, Taiwan, and Thailand.
| Milestone | Vortioxetine | Venlafaxine |
|---|---|---|
| Started | 211 | 226 |
| Completed | 173 | 164 |
| Not completed | 38 | 62 |
| Withdrew: Adverse event | 14 | 32 |
| Withdrew: Lack of efficacy | 8 | 3 |
| Withdrew: Non-compliance | 2 | 4 |
| Withdrew: Protocol violation | 1 | 5 |
| Withdrew: Withdrawal of consent | 5 | 13 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Administrative or other reason(s) | 4 | 3 |
Montgomery and Asberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at two-point intervals. The total score of the ten items ranges from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| units on a scale | Vortioxetine | Venlafaxine |
|---|---|---|
| Change From Baseline in MADRS Total Score at Week 8 | -19.36 ± 0.70 | -18.16 ± 0.68 |
Clinical Global Impression Scale - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients). Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| units on a scale | Vortioxetine | Venlafaxine |
|---|---|---|
| Change in CGI-S Score From Baseline to Week 8 | -2.26 ± 0.09 | -2.12 ± 0.09 |
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not. Higher score = more affected.
| units on a scale | Vortioxetine | Venlafaxine |
|---|---|---|
| CGI-I Score at Week 8 | 1.99 ± 0.08 | 2.14 ± 0.08 |
Hamilton Anxiety Rating Scale (HAM-A) is a 14-item rating scale designed to assess the global anxiety. Each symptom is rated from 0 (absent) to 4 (maximum severity). The total score of the 14 items ranges from 0 to 56. Higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| units on a scale | Vortioxetine | Venlafaxine |
|---|---|---|
| Change in HAM-A Total Score From Baseline to Week 8 | -11.38 ± 0.48 | -10.56 ± 0.47 |
| percentage of patients | Vortioxetine | Venlafaxine |
|---|---|---|
| MADRS Response at Week 8 (Response Defined as a ≥50% Decrease in the MADRS Total Score From Baseline) | 66.5 | 61.4 |
| percentage of patients | Vortioxetine | Venlafaxine |
|---|---|---|
| Remission at Week 8 (Remission Defined as a MADRS Total Score ≤10) | 43.1 | 41.4 |
No measurements were reported for this outcome.
Collected over Baseline to 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine | — | 2/211 (0.9%) | 90/211 (42.7%) |
| Venlafaxine | — | 8/226 (3.5%) | 124/226 (54.9%) |
| Event | Vortioxetine | Venlafaxine |
|---|---|---|
| Suicide attemptPsychiatric disorders | 1/211 | 2/226 |
| DepressionPsychiatric disorders | 1/211 | 0/226 |
| Vertigo positionalEar and labyrinth disorders | 0/211 | 1/226 |
| AstheniaGeneral disorders | 0/211 | 1/226 |
| Intentional overdoseInjury, poisoning and procedural complications | 0/211 | 1/226 |
| Ligament sprainInjury, poisoning and procedural complications | 0/211 | 1/226 |
| AnxietyPsychiatric disorders | 0/211 | 1/226 |
| Major depressionPsychiatric disorders | 0/211 | 1/226 |
| VaricoceleReproductive system and breast disorders | 0/211 | 1/226 |
| Event | Vortioxetine | Venlafaxine |
|---|---|---|
| NauseaGastrointestinal disorders | 51/211 | 53/226 |
| DizzinessNervous system disorders | 18/211 | 32/226 |
| Dry mouthGastrointestinal disorders | 12/211 | 24/226 |
| Decreased appetiteMetabolism and nutrition disorders | 10/211 | 23/226 |
| HeadacheNervous system disorders | 17/211 | 16/226 |
| ConstipationGastrointestinal disorders | 9/211 | 18/226 |
| InsomniaPsychiatric disorders | 5/211 | 17/226 |
| Accidental overdoseInjury, poisoning and procedural complications | 10/211 | 12/226 |
| DyspepsiaGastrointestinal disorders | 11/211 | 9/226 |
The all-patients-treated set (APTS) comprises all randomized patients who took at least one dose of IMP. Baseline age and gender is based on the APTS. Baseline efficacy outcome measures is based on the full-analysis set (FAS).
| Age, Continuous(years) | Vortioxetine | Venlafaxine | Total |
|---|---|---|---|
| Mean | 39.6 ± 12.4 | 40.7 ± 12.3 | 40.1 ± 12.3 |
| Sex: Female, Male(Participants) | Vortioxetine | Venlafaxine | Total |
|---|---|---|---|
| Female | 123 | 139 | 262 |
| Male | 88 | 87 | 175 |
| MADRS total score(units on a scale) | Vortioxetine | Venlafaxine | Total |
|---|---|---|---|
| Mean | 32.3 ± 4.6 | 32.3 ± 4.5 | 32.3 ± 4.6 |
| HAM-A total score(units on a scale) | Vortioxetine | Venlafaxine | Total |
|---|---|---|---|
| Mean | 20.6 ± 7.3 | 21.1 ± 7.0 | 20.9 ± 7.1 |
| CGI-S score(units on a scale) | Vortioxetine | Venlafaxine | Total |
|---|---|---|---|
| Mean | 4.8 ± 0.7 | 4.9 ± 0.7 | 4.9 ± 0.7 |
No study locations are listed for this record.
The record gives a start of May 2012 and a primary completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine